Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will acquire the Watchman minimally invasive stroke-prevention device for patients with atrial fibrillation through its Jan. 19 purchase of Atritech for up to $375 million.